AI in Drug Discovery

Bojan discusses the surprising success of simple RNNs in RNA research, despite limited data. Johnny highlights the hurdles in drug discovery, such as proving the value of AI solutions and the complexities introduced by unsupervised models. The conversation reveals the evolving landscape of AI in the pharmaceutical industry and the need for robust engineering to support these advancements.